Patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) who have been previously treated with two or more tyrosine kinase inhibitors (TKIs).
Patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) who have the T315I mutation.
